October 16, 2022 Clinical Research/Diagn. Microscopy

GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics, and Deliver on Precision Medicine

Chicago, U.S. and Barcelona, Spain – October 16, 2022 – At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legend[i], the first system on its all-new, all-digital PET/CT platform. This cutting-edge system features a brand-new category of digital BGO (dBGO) detector material with a small crystal size that delivers... Read more

September 13, 2022 Bio/Pharma/CRO Clinical Research/Diagn.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy for [18F]flurpiridaz PET compared to SPECT Myocardial Perfusion Imaging (MPI) With a half-life roughly 12 times longer than currently approved cardiac PET radiotracers, if approved,... Read more

August 3, 2022 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Bio-Rad Acquires Curiosity Diagnostics

August 03, 2022 HERCULES, Calif.–(BUSINESS WIRE)– Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland,... Read more

August 1, 2022 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 PAI Top-10

PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company

Enters agreement with intention to divest Applied, Food and Enterprise Services businesses WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 1, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital,... Read more

July 27, 2022 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10

Two PerkinElmer Tests Added to UK’s Updated NICE Diagnostic Guidance for Suspected Preterm Pre-Eclampsia

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that a placental growth factor (PlGF) measurement using its DELFIA® Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA® Xpress sFlt-1 kit (CE-IVD), have been included in an updated diagnostic guidance issued by the United Kingdom’s National... Read more